Rate of lung function decline slows in the 3 years after targeted lung denervation in COPD

Hartman, Jorine E.; Conway, Francesca; Degano, Bruno; Augustijn, Sonja W.S.; Herth, Felix J.F.; Mayr, Anna; Chacaroun, Samarmar; Tonkin, James; Valipour, Arschang; Slebos, Dirk‐Jan

doi:10.1016/j.rmed.2021.106604

Cited by 4 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pre-treatment FEV 1 decline was comparable with the treatment decline we reported earlier in patients undergoing either bronchoscopic lung volume reduction coil or targeted lung denervation treatment [4, 5]. However, the decline was larger compared to earlier reported values in severe COPD.…”

Section: Discussionsupporting

confidence: 84%

See 1 more Smart Citation

Impact of Endobronchial Valve Treatment on Lung Function Decline

Hartman,

Klooster,

Koster

et al. 2023

Respiration

Self Cite

View full text Add to dashboard Cite

Introduction: Endobronchial valve (EBV) treatment has been shown to be beneficial for patients with severe emphysema. The forced expiratory volume in 1 s (FEV1) was found to be significantly higher compared to baseline for up to 3 years after treatment although the magnitude of improvement gradually decreases over time. So far, it has not been investigated whether this treatment decelerates the decline in lung function. Therefore, our aim was to investigate the lung function decline before and after EBV treatment. Methods: We included patients who were treated with EBVs in our hospital, of whom pre-treatment spirometry results were available (at least 4 measurements within at least 2 years before treatment) and who had an annual FEV1 measurement up to 3 years after treatment. Results: In total, 45 patients were included (73% female, FEV1: 28 ± 7% of predicted, residual volume: 232 ± 32% of predicted) who had a mean pre-treatment FEV1 decline of −64 mL/year. Mean FEV1 “decline” after treatment was +13 mL/year, since FEV1 was still above the baseline level at 3-year follow-up. However, the FEV1 decline between 1 and 3 years of follow-up was not significantly different compared to the pre-treatment decline (−73 mL/year, p = 0.179). Conclusions: Our results show that the EBV treatment does not influence the progression of disease in terms of lung function decline. However, the treatment does improve the FEV1 up to a level that is still comparable 3 years after treatment with the baseline level.

show abstract

Section: Discussionsupporting

confidence: 84%

“…Our results show that after 3 years of follow-up, the FEV 1 level was still above the baseline level. This is in positive contrast with other bronchoscopic treatments in which the pre- and post-treatment FEV 1 decline was investigated and in which the FEV 1 had already returned to baseline values after 2 years [ 4 , 5 ].…”

Section: Discussionmentioning

confidence: 94%

Impact of Endobronchial Valve Treatment on Lung Function Decline

Hartman,

Klooster,

Koster

et al. 2023

Respiration

Self Cite

View full text Add to dashboard Cite

show abstract

“…Time-tofirst severe COPD exacerbation was significantly lengthened in the TLD arm (p = 0.04, HR = 0.38) at 2 years post-TLD therapy and trended towards similar attenuation for moderate and severe COPD exacerbations (p = 0.18, HR = 0.71) [15]. TLD also appears to slow decline in lung function in patients with COPD [16]. The aim of this work was to evaluate the patients undergoing TLD as part of the crossover cohort, to establish whether the effects from the randomization phase showing reduced respiratory events post-TLD in COPD are supported.…”

Section: Targeted Lung Denervationmentioning

confidence: 85%

Crossover Patient Outcomes for Targeted Lung Denervation in Moderate to Severe Chronic Obstructive Pulmonary Disease: AIRFLOW-2

Conway

Tonkin

Valipour³

et al. 2022

Respiration

View full text Add to dashboard Cite

Background: Targeted Lung Denervation (TLD) is a potential new therapy for COPD. Radiofrequency energy is bronchoscopically delivered to the airways to disrupt pulmonary parasympathetic nerves, to reduce bronchoconstriction, mucus hypersecretion, and bronchial hyperreactivity. Objectives: This work assesses the effect of TLD on COPD exacerbations (AECOPD) in crossover subjects in the AIRFLOW-2 trial. Method: The AIRFLOW-2 trial is a multicentre, randomized, double-blind, sham-controlled crossover trial of TLD in COPD. Patients with symptomatic COPD on optimal medical therapy with an FEV1 of 30–60% predicted received either TLD or sham bronchoscopy in a 1:1 randomization. Those in the sham arm had the opportunity to cross into the treatment arm after 12 months. The primary end point was rate of respiratory adverse events. Secondary end points included adverse events, changes in lung function and health-related quality of life and symptom scores. Results: Twenty patients were treated with TLD in the crossover phase and were subsequently followed up for 12 months (50% female, mean age 64.1 ± 6.9 years). After TLD, there was a trend towards a reduction in time to first AECOPD (hazard ratio 0.65, p = 0.28, not statistically significant) in comparison to sham follow-up period. There was also a reduction in time to first severe AECOPD in the crossover period (hazard ratio 0.38, p = 0.227, not statistically significant). Symptom scores and lung function showed stability. Conclusions: AIRFLOW-2 crossover data support that of the randomization phase, showing trends towards reduction in COPD exacerbations with TLD.

show abstract

Challenges in clinical practice, biological mechanism and prospects of physical ablation therapy for COPD

Zhu,

Zhou,

et al. 2024

Life Sciences

View full text Add to dashboard Cite

Rate of lung function decline slows in the 3 years after targeted lung denervation in COPD

Cited by 4 publications

References 11 publications

Impact of Endobronchial Valve Treatment on Lung Function Decline

Impact of Endobronchial Valve Treatment on Lung Function Decline

Crossover Patient Outcomes for Targeted Lung Denervation in Moderate to Severe Chronic Obstructive Pulmonary Disease: AIRFLOW-2

Challenges in clinical practice, biological mechanism and prospects of physical ablation therapy for COPD

Contact Info

Product

Resources

About